Spyryx Biosciences is a biopharmaceutical company developing novel therapeutics for obstructive lung diseases based on a discovery of a previously unknown mechanism used by the lung to regulate fluid on the airway surface. This mechanism is dysfunctional in the lungs of CF patients. Spyryx' product's action is independent of the genetic mutations that cause CF, thereby having the potential to provide disease-modifying therapy to the entire CF patient population.
